$AGIO

Analysts issued new ratings for GE Healthcare Technologies (GEHC), Vertex Pharmaceuticals (VRTX) and Agios Pharma (AGIO). Bank of America kept GEHC at Hold with a $74 target; consensus is Moderate Buy at $79.07. Truist reiterated Buy on VRTX with consensus Strong Buy at $562.19. Truist reiterated Buy on AGIO; consensus Moderate Buy targets $41.33.

Gheuens Sarah (Chief Medical Officer) sold 30,000 shares of AGIOS PHARMACEUTICALS, INC. (AGIO) at $30.48 ($0.91M total) on 2026-08-04 under a Rule 10b5-1 trading plan.

AGIOS PHARMACEUTICALS, INC. (AGIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 agio-73026xfyxex991earning.htm EX-99.1 Document Agios Reports Second Quarter 2026 Financial Results and Provides Business Update • Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 milli

Zacks Investment Research says Agios Pharmaceuticals (AGIO) is expected to report Q2 results on July 30. Consensus calls for a quarterly loss of $1.86 per share, up 3.6% YoY, and revenue of $22.68 million, up 82.2%. Zacks reports an Earnings ESP of +12.67% and a Zacks Rank of #3, implying a likely EPS beat.

Agios Pharmaceuticals (AGIO) is scheduled to report Q2 2026 results on July 30 before market open, with earnings released at 6:30 AM ET. The consensus estimate cited for Q2 2026 is revenue of $26.07 million and EPS of -$1.66.

Stocks rose as chipmakers and AI-infrastructure shares gained. The iShares Semiconductor ETF (SOXX) was up over 4%, with Teradyne (TER), Western Digital (WDC), Micron (MU), and Applied Materials (AMAT) among the biggest gainers. Rates moved with 10-year yields around 4.62% amid oil-led inflation expectations. Several companies reported earnings, including 3M, Hasbro, and General Motors.

Stocks rose as chipmakers and AI-infrastructure shares rebounded. The iShares Semiconductor ETF (SOXX) gained over 3%, while Sandisk (SNDK), Micron (MU), Western Digital (WDC), and others rose. Bitcoin hit a 1-month high, lifting Coinbase (COIN) and Circle (CRCL). Hasbro (HAS) reported Q2 net revenue $1.14B and raised guidance; 3M (MMM) beat EPS and lifted outlook.

Agios Pharmaceuticals said it will discontinue development of its sickle cell disease treatment tebapivat after a mid-stage trial showed limited differentiation despite improvements in hemoglobin and hemolysis across doses. Shares fell about 4%. Agios said it will focus on mitapivat, with an FDA target action date of Nov. 1 for sickle cell.

Agios Pharmaceuticals (NASDAQ:AGIO) reported Phase 2 top-line results for tebapivat in sickle cell disease. The 12-week study (59 patients) showed hemoglobin and hemolysis improvements across doses, with 43.8% to 47.1% meeting a primary hemoglobin response versus 33.3% on placebo. Agios said it will stop development because results did not provide sufficient clinical differentiation. AGIO shares were down 7.11% to $37.21.

Agios Pharmaceuticals (NASDAQ:AGIO) shares fell 14% after the company said it will stop developing tebapivat for sickle cell disease based on Phase 2 results. In 59 patients, hemoglobin response rates were 43.8% (2.5 mg), 47.1% (5.0 mg), 29.4% (7.5 mg) versus 33.3% placebo. Agios remains focused on mitapivat, under FDA Priority Review, with a Nov 1, 2026 PDUFA date.